Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
about
The Role of Immunotherapy in Multiple MyelomaAntigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapyInterleukin 12: still a promising candidate for tumor immunotherapy?Therapeutic cancer vaccines: past, present, and futureClinical trials of dendritic cell-based cancer vaccines in hematologic malignanciesImmunotherapy strategies for multiple myeloma: the present and the futureDendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesPreclinical validation of interleukin 6 as a therapeutic target in multiple myelomaDevelopment of Novel Immunotherapies for Multiple MyelomaRecent advances in understanding multiple myelomaExtracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myelomaLenalidomide enhances anti-myeloma cellular immunityNew strategies in the treatment of multiple myeloma.Optical nanomanipulations of malignant cells: controlled cell damage and fusion.Hematopoietic stem cell transplantation-50 years of evolution and future perspectives.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Biophysical effects in off-resonant gold nanoparticle mediated (GNOME) laser transfection of cell lines, primary- and stem cells using fs laser pulses.The immune microenvironment of myelomaPathogenesis beyond the cancer clone(s) in multiple myeloma.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Immunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myelomaHaematological malignancies: at the forefront of immunotherapeutic innovation.Trial watch: Dendritic cell-based interventions for cancer therapyA microfluidic approach towards hybridoma generation for cancer immunotherapyThe 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.Purified dendritic cell-tumor fusion hybrids supplemented with non-adherent dendritic cells fraction are superior activators of antitumor immunity.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.CCR1 as a target for multiple myeloma.Monoclonal antibodies in the treatment of multiple myeloma.Latest advances and current challenges in the treatment of multiple myeloma.Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.
P2860
Q26771144-6319A6D8-A62B-40E6-B240-49B1DBB8692EQ26824676-C89D13FD-ADCC-4ED0-B42A-3DC8C7D4374EQ26861559-53376180-36E6-422D-BF4A-2F13E72AD74AQ26863283-97D4FD4A-8631-42D8-8F8C-E47CD83A2161Q26864603-37DC731C-0B29-49F4-9E9D-77F4B495E42EQ27021939-E58C17DE-7E62-4374-B9DC-7DB7FBD693B0Q27023621-FD007C24-8E02-4970-9D53-CB022843FDB1Q27026478-74887176-63C9-4A57-BF0D-4572896C7BE6Q27027729-CAFDE19A-94EA-453C-BF5C-C81A5D80E3E0Q28066890-B4231930-91D7-45B5-812D-9BEFFE7F0CF8Q28070331-6961829B-D047-4B16-BFA3-B0897854DC41Q28077635-5057B2E0-9D40-4D8F-BDD4-EC1F66AA00EEQ33903133-88EA03D3-49B3-42F9-A412-8866449A75AEQ33958520-130A71D7-62F0-40CF-8742-8A5DD3DD080CQ34202505-9475ED85-B76D-44F8-A796-34801F74A0D6Q34463419-0CBF578D-63BE-4319-966C-77133D3D48EDQ34773850-625016ED-59E4-4042-9AED-EB7DBE6EDC85Q34898366-171A0704-8576-4980-8174-4EA316479E24Q35319588-E4B9FEAA-42C6-46CA-9559-027ACDCB5A50Q35603152-9123825C-F757-4DEA-A9CA-6A8C204DC200Q35607266-37C28CBA-F932-4337-A1AD-FE34C63B0F07Q35677112-6C19DEAE-9CDF-4AD6-8832-A64568487660Q35852574-9920E47E-466A-49B0-814D-FEB992F456E0Q35865581-4043037D-5B7D-47CB-A553-C633E3C15C8DQ35880618-55EC2DEA-1171-4CE5-8F49-4C117EDB0828Q36388529-92345DE7-71B6-42A3-9776-C002F276F471Q36629413-364B18C4-2799-4EE2-9174-459AF17C96E6Q36709283-C0ECB392-B629-491D-BE2D-B354332E154BQ37071139-AB4FFD7D-3219-4CD1-90CC-A7EE1C00779CQ37128664-16049FB9-7AB8-4542-82F5-6B2DAD4140A8Q37510538-5BC43D2D-80D2-490F-A336-172F85164DBAQ37517482-5652DA8B-3472-442C-A18E-815F78B4F76CQ37879210-BEF8260D-478C-4D76-BF0D-490C67354A6DQ37903377-432EDFA3-B9A7-4A58-B352-FADD7970DD77Q37986287-6D909E46-2881-4E65-9E64-43460E3C5A85Q37991701-4910BC0E-8B20-459C-9110-47724A8A2C41Q38002844-6684A492-DB4D-486C-95C1-DBDD744754DCQ38008379-3E1D6D6B-DD21-4B83-989E-A561E5E9C6DAQ38035044-D5CA5655-C67A-4B79-AEEF-9538953D4AFBQ38059517-2FEA2467-BE7E-4B2B-B297-AA3F03334090
P2860
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Vaccination with dendritic cel ...... patients with multiple myeloma
@ast
Vaccination with dendritic cel ...... patients with multiple myeloma
@en
type
label
Vaccination with dendritic cel ...... patients with multiple myeloma
@ast
Vaccination with dendritic cel ...... patients with multiple myeloma
@en
prefLabel
Vaccination with dendritic cel ...... patients with multiple myeloma
@ast
Vaccination with dendritic cel ...... patients with multiple myeloma
@en
P2093
P2860
P1433
P1476
Vaccination with dendritic cel ...... patients with multiple myeloma
@en
P2093
Baldev Vasir
Claire Macnamara
David Avigan
Dilani Dombagoda
Donald Kufe
Donna Fitzgerald
Edie Weller
Jacalyn Rosenblatt
James D Levine
Karen Francoeur
P2860
P304
P356
10.1182/BLOOD-2010-04-277137
P407
P577
2010-10-28T00:00:00Z